Stranded Technologies Podcast · Infinita City

Ep. 100: A Conversation with Dr. Mary Ruwart: The Lost Innovation Cost of the FDA, and How Founders Can Reclaim the Right to Build

·1 hr 17 min·5 clips

Mary says the FDA stretched drug development from 4 years to 14 years.

The episode starts with a wide-angle view of frontier technology and the barriers that keep abundance from arriving. The host introduces Ruwart as a writer and activist who has spent years arguing that regulation can do serious damage when it becomes self-protecting. He says her book is meticulously argued and that it clarified ideas he had been circling for a while. From there, the discussion moves from the book to the practical question of how regulation shapes medicine. The focus lands on the FDA as an institution that can slow or block innovation even when the science and the need are both clear. The conversation treats that slowdown as a real cost, not a small bureaucratic annoyance. It then turns to the fear people feel when working near medical regulation. The host asks whether that fear is reasonable or exaggerated. Ruwart says it is reasonable. She points to a rare muscle-wasting disease and an orphan drug case as an example of how regulatory demands can drift away from reality. In her account, the agency kept demanding more and more studies from a company that had already seen success with a drug. The studies would have required an enormous number of children and even invasive biopsies on weakened muscles. That, she says, creates both practical and ethical problems. The company CEO eventually resigned in hopes that the FDA would finally move. Approval still took years. The episode also touches on cases where developers were so frustrated by the FDA that some drugs became available in Britain but not in the United States. As the discussion goes on, the pattern becomes harder to miss: the issue is not just delay, but institutional hostility that can shape the fate of a treatment. The host and Ruwart keep coming back to the same pressure point, which is whether the system is preserving safety or just protecting itself. The tone stays analytical rather than theatrical. The conversation assumes the listener can follow a line of reasoning about incentives, power, and the cost of caution. At the same time, it does not flatten the human side of the story, because the examples always involve real patients and real companies. The interview gives the guest room to build her case without constant interruption, which lets the logic pile up in a deliberate way. By the end, the episode settles into a broad argument for lowering the barriers that keep founders, researchers, and patients from moving faster. The closing frame is less about one drug than about a whole system of delayed possibility. It is an appeal to treat innovation as something worth defending, not just something to regulate.

As heard by us

A hard look at how regulation can slow medical progress.

Mary Ruwart joins the host for a direct talk about over-regulation, with the FDA at the center of the argument. The episode leans on one orphan-drug case, with a company, a CEO resignation, and years of delay before approval, so the point never floats off into abstraction.

Read the full review in PlayNext →

Why you'd press play

Hear the case for moving faster when regulation is the thing standing in the way.

Read the full recommendation in PlayNext →

Listen to the show on

Apple Podcasts Spotify

Play clips from this episode More from Stranded Technologies Podcast